Robinhood Asset Management LLC Invests $17.53 Million in Amgen Inc. $AMGN

Robinhood Asset Management LLC bought a new position in Amgen Inc. (NASDAQ:AMGN) during the 4th quarter, Holdings Channel.com reports. The institutional investor bought 53,544 shares of the medical research company’s stock, valued at approximately $17,526,000. Amgen comprises about 1.4% of Robinhood Asset Management LLC’s holdings, making the stock its 17th largest holding.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Board of the Pension Protection Fund acquired a new position in shares of Amgen in the 4th quarter valued at $26,000. Howard Hughes Medical Institute acquired a new stake in shares of Amgen during the 2nd quarter worth $32,000. Olistico Wealth LLC acquired a new stake in shares of Amgen during the 4th quarter worth $33,000. Cloud Capital Management LLC purchased a new position in shares of Amgen in the 3rd quarter worth $34,000. Finally, Saranac Partners Ltd acquired a new position in Amgen in the third quarter valued at $37,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Down 1.5%

AMGN opened at $342.57 on Tuesday. The firm’s 50 day moving average is $363.51 and its 200-day moving average is $333.65. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The firm has a market capitalization of $184.67 billion, a P/E ratio of 24.07, a P/E/G ratio of 3.45 and a beta of 0.47.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. During the same period in the prior year, the firm earned $5.31 earnings per share. The business’s quarterly revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s payout ratio is presently 70.84%.

Analyst Ratings Changes

Several brokerages have commented on AMGN. Truist Financial upped their price target on Amgen from $318.00 to $319.00 and gave the stock a “hold” rating in a research note on Thursday, January 8th. Morgan Stanley boosted their target price on Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 4th. The Goldman Sachs Group increased their target price on shares of Amgen from $403.00 to $415.00 and gave the stock a “buy” rating in a research report on Wednesday, February 4th. Citigroup lifted their price target on shares of Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a research report on Wednesday, February 4th. Finally, Daiwa Securities Group boosted their price objective on shares of Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 10th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $354.60.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.